Full Text View
Tabular View
Study Results
Related Studies
Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD
This study has been completed.
Study NCT00080288   Information provided by Cephalon
First Received: March 25, 2004   Last Updated: August 14, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Excessive Sleepiness
Shift Work Sleep Disorder
Additional conditions recognized in this trial
Disease
Disorders of Excessive Somnolence
Sleep Disorders
Sleep Disorders, Circadian Rhythm
More general conditions related to this trial
Chronobiology Disorders
Disorders of Environmental Origin
Dyssomnias
Mental Disorders
Nervous System Diseases
Neurologic Manifestations
Occupational Diseases
Pathologic Processes
Signs and Symptoms
Sleep Disorders, Intrinsic
Interventions listed in this trial
Armodafinil 150 mg/day
Placebo
Additional drug interventions recognized in this trial
Modafinil
More general drug interventions related to this trial
Central Nervous System Agents
Central Nervous System Stimulants
Neuroprotective Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
Cephalon


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services